Neonatal HypoglycemiaNCT07133906
Accuracy of Interstitial Continuous Glucose Sensors in Neonates
An observational study of Neonatal Hypoglycemia and Gestational Diabetes, run by Women and Infants Hospital of Rhode Island.
Trial summary
Low blood sugar in newborns is common and if prolonged or untreated may place them at increased risk for later learning and behavior challenges. Currently, we measure newborn glucose with at least four painful heel sticks, missing one in four episodes of low blood sugar. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Neonatal Hypoglycemia, Gestational Diabetes, Maternal Obesity Complicating Pregnancy
- What is being tested?
- Continuous glucose monitoring and Cerebral near-infrared spectroscopy
- Type of treatment
- Medical device
- How many people
- 114 participants
- Where
- No sites listed yet
- Study dates
- Sep 2025to Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Antenatal floor, labor and delivery unit (L\&D), neonatal intensive care unit (NICU), mother baby unit (MBU), and obstetrics and diabetes clinics at Women and Infants Hospital
Who may be able to join
- women aged 18 years or older
- speaks English, Spanish, Portuguese, or Haitian Creole
- pregnant >24 weeks gestation with singleton pregnancy
Who cannot join
- known concomitant maternal or fetal condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff
- plans to deliver at a hospital other than Women and Infants Hospital of Rhode Island
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Low blood sugar in newborns is common and if prolonged or untreated may place them at increased risk for later learning and behavior challenges. Currently, we measure newborn glucose with at least four painful heel sticks, missing one in four episodes of low blood sugar. The goal of this observational study is to develop a less invasive approach to glucose monitoring, developed for newborns, that provides more frequent glucose measurements. We will also measure how a pregnant woman's health impacts newborn glucose, and how newborn glucose is linked to brain oxygen saturation and development.
Read the detailed description
Glycemic control in newborns remains a major challenge for neonatal care. One third of U.S. infants are screened for neonatal hypoglycemia (NH) with repeated, painful heel sticks, most commonly based on dichotomous maternal diabetes determination or newborn size. Yet, less than 50% of these infants subsequently develop and are treated for hypoglycemia. If treatment is needed, it is based on "operational thresholds" that do not account for the actual effect of glycemia on brain metabolism, nor for its long-term consequences, and potentially expose infants to unnecessary treatment that may further amplify harm. Thus, both screening and treatment for NH lack precision and are not driven by physiology or outcome.
Improving NH risk stratification requires maternal metabolic and neonatal glycemic characterization in a cohort that includes dyads considered at-risk, with comparison to not-at-risk controls. Establishing "functional thresholds" for glycemic treatment requires evaluation of reliable bedside measurable proxies of brain metabolic "health" during the neonatal period. Further, these need to contextualised within the longitudinal trajectory of the domains known to be impacted by NH, namely executive and visual motor function. These critical domains have not been investigated together in one pre-birth, longitudinal cohort, and this knowledge gap has limited advancements in NH care.
- The primary objective of this observational study is to characterize the Abbott FreeStyle Libre 3 Pro continuous glucose monitoring system performance with respect to point of care whole blood reference in neonates.
- A secondary objective is to determine maternal and neonatal predictors of NH and child neurodevelopment.
- A secondary objective is to identify glycemic and cerebral saturation thresholds of exposure linked to adverse neurodevelopment.
Study Design
- Non-randomized, single arm, single-center, prospective, observational study
Study Procedures Visit 1 (V1) t: 30-36 weeks' gestation
Procedures:
- Complete the following electronic surveys and questionnaires: Demographics, Holmes-Rahe Life Stress Inventory, Infant Feeding Intentions Questionnaire, and the Fat/Sugar/Fruit/Vegetables Screener.
- Participants will be provided blood self-collection kits and asked to provide fasting blood samples at 35-37 weeks gestation, to be archived for later measurement of metabolic markers.
Visit 2 (V2): post-delivery in hospital
Procedures:
- All infants will have blinded FreeStyle Libre 3 Pro Continuous Glucose Monitors placed on the lateral thigh by the PI or trained staff which will be continued to hospital discharge or for 10 days, depending which occurs first.
- Near Infrared Spectroscopy (NIRS) probe will be placed on the forehead of the infant, connected to a monitor that will be blinded (covered) to the parents and clinical team.
- Infants will have additional research blood drawn (50 uL) by heel stick or venipuncture (based on clinical method of blood collection) at least twice.
- Any extra blood available will be used to measure ketones and lactate using a hand-held meter.
- Every effort will be made to align research blood draws with clinical draws, however, if this is not possible, enrolled infants will have an additional 1-2 heel sticks daily for research purposes.
- Infant body composition will be measured using air displacement plethysmography (PeaPod TM) and bioimpedance assay within 72 hours of life.
- Infant weight and length will be measured.
- The Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) will be administered by an NNNS trained and certified staff.
- Additional clinical data will be extracted from the both the maternal and infant medical record.
Visit 3 (V3): 6 months of life (between 5 and 7 months of age) - Parent will complete the following electronic questionnaires: 6-Month Ages and Stages Questionnaire, Breastfeeding Status Questionnaire, and the Infant Feeding Practices Survey (6 Months).
Visit 4 (V4): 1 year of life (between 11 and 13 months of age)
- Procedure: Parent will complete the following electronic questionnaires: Breastfeeding Status Questionnaire, Infant Feeding Practices Survey (12 Months), 1-Year Ages and Stages Questionnaire, Child Health Questionnaire, and the Brief Infant Toddler Social and Emotional Assessment (BITSEA).
Additional clinical data will be abstracted from the medical record of the mother and infant after discharge. Study staff will complete chart reviews for key pregnancy health variables outlined in the "Medical Record Abstraction Form" and enter into study database.
Cord blood will be collected and archived for a subset of subjects.
- Conditions
- Neonatal Hypoglycemia, Gestational Diabetes, Maternal Obesity Complicating Pregnancy, Small-for-gestational Age, Large-for-gestational Age
- Being tested
- Continuous glucose monitoring, Cerebral near-infrared spectroscopy
- Medical subject headings
- Diabetes, Gestational
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous glucose monitoringDevice
A blinded Abbott Freestyle Libre 3 Pro will be placed on the newborn
Cerebral near-infrared spectroscopyDevice
Blinded cerebral near infrared spectroscopy will be assessed
| Study group | Role | What they receive |
|---|---|---|
| Pregnant women >24 weeks gestation and their infants | Pregnant women >24 weeks gestation; infants of pregnant women >24 weeks gestation, including 11 infants of women with gestational diabetes, 11 infants of women with type II diabetes, 11 infants of women with type I diabetes, 6 small-for-gestational age (SGA) infants, 6 large-for-gestational age (LGA) infants, and 12 control infants who are not considered at-risk for hypoglycemia. Receives: Device: Continuous glucose monitoring; Device: Cerebral near-infrared spectroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Point Accuracy: System agreement analysis
Number and percent of glucose monitoring (GM) sensor results within the intervals +/- 20% of glucose reference throughout the system measuring range
Measured: From time of birth to discharge, an average of 3 days
Secondary outcomes (3)
Episodes of neonatal hypoglycemia (NH) by risk factors
Count of neonatal hypoglycemia (NH) episodes in infants born with various maternal and neonatal risk factors (maternal diabetes, maternal gestational glucose intolerance, maternal obesity, fetal growth abnormalities, maternal beta blockers, and preterm delivery) or no risk factors.
Measured: Between birth to 72 hours after birth
NNNS scores
NNNS subscale score quartiles
Measured: From time of birth to 72 hours after birth, at an average of 48 hours of age
ASQ scores
Ages and Stages (ASQ) scores
Measured: 6 months and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2025
- Study startSep 2025 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neonatal HypoglycemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 114 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sarbattama Rimi Sen, Women and Infants Hospital of Rhode Island
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07133906
- Sponsor's protocol ID
- 2177993
- Status last verified
- Aug 2025
- First submitted
- 22 Jul 2025
- Last updated
- 21 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Accuracy of Interstitial Continuous Glucose Sensors in Neonates
- ClinicalTrials.gov ID
- NCT07133906
- Acronym / sponsor ID
- 2177993
- Conditions
- Neonatal Hypoglycemia, Gestational Diabetes, Maternal Obesity Complicating Pregnancy, Small-for-gestational Age, Large-for-gestational Age
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 114 participants (estimated)
- Lead sponsor
- Women and Infants Hospital of Rhode IslandUniversity, hospital or other
- Study start
- Sep 2025 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 21 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Low blood sugar in newborns is common and if prolonged or untreated may place them at increased risk for later learning and behavior challenges. Currently, we measure newborn glucose with at least four painful heel sticks, missing one in four episodes of low blood sugar. The goal of this observational study is to develop a less invasive approach to glucose monitoring, developed for newborns, that provides more frequent glucose measurements. We will also measure how a pregnant woman's health impacts newborn glucose, and how newborn glucose is linked to brain oxygen saturation and development.
Detailed description
Glycemic control in newborns remains a major challenge for neonatal care. One third of U.S. infants are screened for neonatal hypoglycemia (NH) with repeated, painful heel sticks, most commonly based on dichotomous maternal diabetes determination or newborn size. Yet, less than 50% of these infants subsequently develop and are treated for hypoglycemia. If treatment is needed, it is based on "operational thresholds" that do not account for the actual effect of glycemia on brain metabolism, nor for its long-term consequences, and potentially expose infants to unnecessary treatment that may further amplify harm. Thus, both screening and treatment for NH lack precision and are not driven by physiology or outcome.
Improving NH risk stratification requires maternal metabolic and neonatal glycemic characterization in a cohort that includes dyads considered at-risk, with comparison to not-at-risk controls. Establishing "functional thresholds" for glycemic treatment requires evaluation of reliable bedside measurable proxies of brain metabolic "health" during the neonatal period. Further, these need to contextualised within the longitudinal trajectory of the domains known to be impacted by NH, namely executive and visual motor function. These critical domains have not been investigated together in one pre-birth, longitudinal cohort, and this knowledge gap has limited advancements in NH care.
- The primary objective of this observational study is to characterize the Abbott FreeStyle Libre 3 Pro continuous glucose monitoring system performance with respect to point of care whole blood reference in neonates.
- A secondary objective is to determine maternal and neonatal predictors of NH and child neurodevelopment.
- A secondary objective is to identify glycemic and cerebral saturation thresholds of exposure linked to adverse neurodevelopment.
Study Design
- Non-randomized, single arm, single-center, prospective, observational study
Study Procedures Visit 1 (V1) t: 30-36 weeks' gestation
Procedures:
- Complete the following electronic surveys and questionnaires: Demographics, Holmes-Rahe Life Stress Inventory, Infant Feeding Intentions Questionnaire, and the Fat/Sugar/Fruit/Vegetables Screener.
- Participants will be provided blood self-collection kits and asked to provide fasting blood samples at 35-37 weeks gestation, to be archived for later measurement of metabolic markers.
Visit 2 (V2): post-delivery in hospital
Procedures:
- All infants will have blinded FreeStyle Libre 3 Pro Continuous Glucose Monitors placed on the lateral thigh by the PI or trained staff which will be continued to hospital discharge or for 10 days, depending which occurs first.
- Near Infrared Spectroscopy (NIRS) probe will be placed on the forehead of the infant, connected to a monitor that will be blinded (covered) to the parents and clinical team.
- Infants will have additional research blood drawn (50 uL) by heel stick or venipuncture (based on clinical method of blood collection) at least twice.
- Any extra blood available will be used to measure ketones and lactate using a hand-held meter.
- Every effort will be made to align research blood draws with clinical draws, however, if this is not possible, enrolled infants will have an additional 1-2 heel sticks daily for research purposes.
- Infant body composition will be measured using air displacement plethysmography (PeaPod TM) and bioimpedance assay within 72 hours of life.
- Infant weight and length will be measured.
- The Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) will be administered by an NNNS trained and certified staff.
- Additional clinical data will be extracted from the both the maternal and infant medical record.
Visit 3 (V3): 6 months of life (between 5 and 7 months of age) - Parent will complete the following electronic questionnaires: 6-Month Ages and Stages Questionnaire, Breastfeeding Status Questionnaire, and the Infant Feeding Practices Survey (6 Months).
Visit 4 (V4): 1 year of life (between 11 and 13 months of age)
- Procedure: Parent will complete the following electronic questionnaires: Breastfeeding Status Questionnaire, Infant Feeding Practices Survey (12 Months), 1-Year Ages and Stages Questionnaire, Child Health Questionnaire, and the Brief Infant Toddler Social and Emotional Assessment (BITSEA).
Additional clinical data will be abstracted from the medical record of the mother and infant after discharge. Study staff will complete chart reviews for key pregnancy health variables outlined in the "Medical Record Abstraction Form" and enter into study database.
Cord blood will be collected and archived for a subset of subjects.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pregnant women >24 weeks gestation and their infants | – | Device: Continuous glucose monitoring, Device: Cerebral near-infrared spectroscopyPregnant women >24 weeks gestation; infants of pregnant women >24 weeks gestation, including 11 infants of women with gestational diabetes, 11 infants of women with type II diabetes, 11 infants of women with type I diabetes, 6 small-for-gestational age (SGA) infants, 6 large-for-gestational age (LGA) infants, and 12 control infants who are not considered at-risk for hypoglycemia. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Antenatal floor, labor and delivery unit (L\&D), neonatal intensive care unit (NICU), mother baby unit (MBU), and obstetrics and diabetes clinics at Women and Infants Hospital
Key inclusion criteria (3 listed)
- women aged 18 years or older
- speaks English, Spanish, Portuguese, or Haitian Creole
- pregnant >24 weeks gestation with singleton pregnancy
Key exclusion criteria (2 listed)
- known concomitant maternal or fetal condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff
- plans to deliver at a hospital other than Women and Infants Hospital of Rhode Island
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous glucose monitoringA blinded Abbott Freestyle Libre 3 Pro will be placed on the newborn | Device | Pregnant women >24 weeks gestation and their infants |
| Cerebral near-infrared spectroscopyBlinded cerebral near infrared spectroscopy will be assessed | Device | Pregnant women >24 weeks gestation and their infants |
Primary outcome
Point Accuracy: System agreement analysis
Time frame: From time of birth to discharge, an average of 3 days
Number and percent of glucose monitoring (GM) sensor results within the intervals +/- 20% of glucose reference throughout the system measuring range
3 secondary outcomes
Episodes of neonatal hypoglycemia (NH) by risk factors
Time frame: Between birth to 72 hours after birth
NNNS scores
Time frame: From time of birth to 72 hours after birth, at an average of 48 hours of age
ASQ scores
Time frame: 6 months and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Neonatal Hypoglycemia
RecruitingObservational study
Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
Congenital Disorders of Glycosylation
RecruitingPhase 4
Pasteurised Donor Human Milk Supplementation for Term Babies
Neonatal Hypoglycemia, Metabolic Complication
Not yet recruiting
Umbilical Cord Glucose
Congenital Hyperinsulinism (CHI)
Active, not recruitingPhase 2
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
Congenital Hyperinsulinism
Recruiting
Automated Insulin for Management of Intrapartum Glycemia
Type 1 Diabetes (T1D), Pregnancy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Neonatal Hypoglycemia and Gestational Diabetes, run by Women and Infants Hospital of Rhode Island.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sarbattama Sen, MD (401-274-1122, ssen@carene.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Point Accuracy: System agreement analysis (time frame: From time of birth to discharge, an average of 3 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2025.